Last reviewed · How we verify
T89 Group C
At a glance
| Generic name | T89 Group C |
|---|---|
| Also known as | Dantonic®, Salvtonic®, Compound Danshen Dripping Pills |
| Sponsor | Tasly Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- U/S Guided Rhomboid Intercostal Block Combined With Sub-Serratus Plane Block vs Type 2 Pectoral Nerve Block (NA)
- Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T89 Group C CI brief — competitive landscape report
- T89 Group C updates RSS · CI watch RSS
- Tasly Pharmaceuticals, Inc. portfolio CI